Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03381183
Title IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

hypopharynx cancer

laryngeal squamous cell carcinoma

paranasal sinus cancer

head and neck squamous cell carcinoma

oropharynx cancer

oral squamous cell carcinoma

Therapies

Cyclophosphamide + Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.